Physician profile
Daniel Christopher Dollar
NPI 1922442706
$1,422.93
in general payments reported to CMS, 2019-2025
22 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $165 · 2022: $377 · 2023: $449 · 2024: $277 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $881.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $243.35 | 2021-2023 | |
| Novo Nordisk INC | $173.09 | 2022-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $106.49 | 2021-2025 | Mounjaro, Zepbound |
| Lundbeck LLC | $106.00 | 2023-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $97.75 | 2023-2025 | Rexulti, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $96.87 | 2021-2023 | Trintellix |
| Avanir Pharmaceuticals, INC. | $92.74 | 2021-2022 | |
| Pfizer INC. | $79.31 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $57.23 | 2022-2024 | Verquvo |
| Exact Sciences Corporation | $52.50 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $50.15 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $38.53 | 2022-2023 | Vraylar |
| Amgen INC. | $35.05 | 2023-2024 | Otezla, Repatha |
| Astellas Pharma US INC | $34.44 | 2024 | Veozah |
| Astrazeneca Pharmaceuticals Lp | $33.02 | 2022-2023 | Farxiga |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.15 | 2024 | Caplyta |
| Amarin Pharma, INC. | $19.63 | 2021 | |
| Idorsia Pharmaceuticals US INC | $19.19 | 2023 | Quviviq |
| Mylan Specialty L.P. | $18.95 | 2023 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.01 | 2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $14.91 | 2025 | Keveyis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Dollar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.